Evidence map›Paper›PMID 40434500›Full record

ArticleEJNMMI research2025

Metabolic parameters on baseline and early [

Bernies van der Hiel, Berlinda J de Wit-van der Veen, Alfons J M van den Eertwegh, Wouter V Vogel, Marcel P M Stokkel, Marta Lopez-Yurda, Ronald Boellaard, Ellen W Kapiteijn, Geke A P Hospers, Maureen J B Aarts and 5 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02414750 (A Phase II, Open-Label, Multicenter Study of Vemurafenib Plus Cobimetinib), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02414750 phase2terminatednot on this map

A Phase II, Open-Label, Multicenter Study of Vemurafenib Plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction With Positron Emission Tomography and Tumor Characteristics

TypeinterventionalSponsorNetherlands Working Group on Immunotherapy of OncologyRan2014 to 2020Enrolled78ConditionsMetastatic MelanomaArmsVemurafenib plus cobimetinib, Positron Emission Tomography, Tissue sampling, Blood sampling
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bernies van der HielDepartment of Nuclear Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121- Room C0.137, Amsterdam, 1066 CX, The Netherlands. b.vd.hiel@nki.nl.ORCID http://orcid.org/0000-0001-8158-405X
Berlinda J de Wit-van der VeenDepartment of Nuclear Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121- Room C0.137, Amsterdam, 1066 CX, The Netherlands.
Alfons J M van den EertweghDepartment of Medical Oncology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Wouter V VogelDepartment of Nuclear Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121- Room C0.137, Amsterdam, 1066 CX, The Netherlands.
Marcel P M StokkelDepartment of Nuclear Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121- Room C0.137, Amsterdam, 1066 CX, The Netherlands.
Marta Lopez-YurdaDepartment of Biometrics, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Ronald BoellaardDepartment of Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Ellen W KapiteijnDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Geke A P HospersDepartment of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
Maureen J B AartsDepartment of Medical Oncology, GROW-School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands.
Filip Y F L de VosDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Marye J Boers-SonderenDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Astrid A M van der VeldtDepartment of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
Jan Willem B de GrootDepartment of Medical Oncology, Isala Oncology Center, Zwolle, The Netherlands.
John B A G HaanenDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.

Funding

F. Hoffmann-La Roche F. Hoffmann-La Roche
6 · The paper itself

Abstract

background[

resultsSeventy-five patients with metastatic melanoma were enrolled in a multi-center trial and treated with vemurafenib/cobimetinib. [

conclusionThis study supports the use of MTV and TLG as robust predictive markers for PFS in advanced melanoma treated with BRAF/MEK-inhibitors. Monitoring early PET parameters changes can provide valuable insights into therapeutic response and disease progression.

trial registrationClinicaltrials.gov identifier: NCT02414750. Registered 10 April 2015, retrospectively registered.

Indexed as

BRAF mutationMelanomaMetabolic tumor volumePositron emission tomographyProgression-free survivalStandardized uptake valueTargeted therapyTotal lesion glycolysis

Identifiers

PMID40434500
PMCPMC12119442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.